Sanofi Respiratory Deal History & Licensing Activity
Sanofi Respiratory is a large pharma headquartered in France. Over the past three years, Sanofi Respiratory has been involved in 4 licensing and acquisition transactions, with a primary focus on Small Molecules (6 deals).
Deals (12mo)
4
Active Trials
20
Top Modality
Small Molecules
Focus Area
Mega Deals
Sanofi Respiratory Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Sanofi Respiratory in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| rovadicitinib | Sanofi | Small Molecules | Unknown | license | Jul 1, 2026 |
| rovadicitinib | Sanofi | Small Molecules | Unknown | license | Jun 27, 2026 |
| AXPAXLI | Sanofi | Other | Phase 3 | acquisition |
Sanofi Respiratory Pipeline Focus
Therapeutic areas and modalities where Sanofi Respiratory is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Sanofi Respiratory Strategic Signals
Key indicators of Sanofi Respiratory's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches Sanofi Respiratory's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Ophthalmology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for ophthalmology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Sanofi Respiratory Licensing & Deal Activity
Sanofi Respiratory is a large pharma company based in France that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Sanofi Respiratory ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Sanofi Respiratory include Mega Deals (4 deals and trials), Immunology (2 deals and trials), and Ophthalmology (2 deals and trials). In terms of modality, Sanofi Respiratory has shown particular interest in small molecules, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Sanofi Respiratory and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Sanofi Respiratory's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.